A

Alnylam Pharmaceuticals

Develops RNAi-based therapies for genetic diseases

Associate Director - Clinical Pharmacology

Quantitative Biology & BiostatisticsConfirmed live in the last 24 hours
Full-timeUnited States$175.8k - $237.8kIn-person

About the Job

Requirements

  • Ph.D. or Pharm.D. in a relevant field such as Pharmacokinetics, Pharmacometrics, or Clinical Pharmacology, with in-depth experience in the pharmaceutical or biotechnology industry.
  • In-depth knowledge of clinical pharmacology, pharmacokinetics, modeling and simulation, pharmacokinetic/pharmacodynamic principles, absorption, distribution, metabolism and excretion, and clinical data interpretation.
  • In-depth knowledge of international guidelines related to Clinical Pharmacology and Pharmacometrics.
  • Proficiency using Phoenix WinNonlin, R, NONMEM, or other pharmacokinetic, modeling, and data visualization software.
  • Ability to function in a highly matrixed team environment and work independently.
  • Fluency in English, both verbal and written.

Responsibilities

  • Represent Clinical Pharmacology independently and provide clinical pharmacology support and guidance to clinical-stage project teams.
  • Lead the analysis, interpretation, integration, and reporting of clinical pharmacology data.
  • Conduct pharmacokinetic and pharmacokinetic/pharmacodynamic analyses to guide clinical development decisions.
  • Provide clinical pharmacology input for regulatory submissions, including briefing documents, Investigational New Drug (IND) applications, Clinical Trial Applications (CTAs), and New Drug Applications (NDAs).
  • Prepare and independently contribute appropriate documents or sections of clinical protocols, Investigator Brochures, and Clinical Study Reports relating to Clinical Pharmacology studies or data.
  • Partner closely with Research, Bioanalytical, Clinical, Regulatory, Project Management, and other R&D functions.
  • Prepare abstracts and manuscripts for publication.

About the Company

Alnylam Pharmaceuticals

Develops RNAi-based therapies for genetic diseases

Alnylam Pharmaceuticals develops RNA interference (RNAi) therapeutics to silence disease-causing genes, aiming to treat rare genetic disorders. Its products work by using RNA molecules that block gene expression, reducing the impact of specific genetic diseases. The company differentiates itself by concentrating on RNAi-based drugs for rare diseases and by building a pipeline through large clinical programs and strategic partnerships, such as commercialization deals in the Gulf States and collaborations with investors. Revenue comes from approved drug sales, licensing agreements, strategic collaborations, and related services like genetic testing and counseling. The company’s goal is to advance and commercialize RNAi therapies to improve outcomes for patients with genetic disorders, expanding its portfolio through partnerships and investments.

Company size
1,001-5,000
Company stage
IPO
Headquarters
Cambridge, MA
Founded
2002

Recently Posted Jobs

Explore more opportunities at Alnylam Pharmaceuticals

See more jobs